Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
On Jan. 25, 2021, the National Institutes of Health (NIH) announced that in large clinical trial conducted worldwide,…
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
On Dec. 15, 2020, Aurinia Pharmaceuticals announced the funding and initiation of an open-label exploratory trial evaluating the…
On Nov. 17, 2020, the proposed settlements between the federal government and OxyContin maker Purdue Pharma and its…
On Oct. 28, 2020, Seagen announced the closing of a $1.0 billion equity investment by Merck in 5.0…
On Oct. 21, 2020, Purdue Pharma announced that it had entered into an agreement with the U.S. Department…
On Oct. 20, 2020, the U.S. Department of Defense announced an $87 million, seven-year award to the BioIndustrial…
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 6, 2020, the National Science Foundation (NSF) announced investments in 24 new projects to drive future…
On Oct. 5, 2020, Bristol-Myers and MyoKardia announced a definitive merger agreement under which Bristol Myers Squibb will…
On Oct. 5, 2020, Corvus Pharmaceuticals announced updated data from its ongoing Phase 1 study investigating the potential…
On Oct. 2, 2020, the World Health Organization (WHO) and the Kingdom of Saudi Arabia signed a contribution…
On Oct. 1, 2020, Johnson & Johnson announced it had successfully completed its acquisition of Momenta Pharmaceuticals, a…
On Sept. 28, 2020, the U.S. Departments of Defense and Health and Human Services signed a $20 million…
On Sept. 24, 2020, the U.S. Department of Health and Human Services and the U.S. Food and Drug…
On Sept. 15, 2020, the Tufts Center for the Study of Drug Development reported that new anti-infective drugs…
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
On Sept. 2, 2020, Mesoblast announced that it had received ethics approval to include Australian hospitals in the…
On Sept. 1, 2020, Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara (sarilumab) at…
On Aug. 17, 2020, Sanofi and Principia Biopharma announced a definitive agreement under which Sanofi will acquire all…
On Aug. 7, 2020, Novavax and Takeda Pharmaceutical announced a partnership for the development, manufacturing and commercialization of…
On Aug. 4, 2020, Cocrystal Pharma announced the publication of preclinical animal studies of coronavirus antiviral compounds in…
On Jul. 28, 2020, the U.S. International Development Finance Corp. (DFC) announced that it had signed a letter…